Kyverna Therapeutics secures $25M to treat autoimmune disorders
January 14, 2020
Share:
Kyverna Therapeutics has raised a $25 million Series A from Vida Ventures, Westlake Village BioPartners and Gilead Sciences. Founded in 2018 and based in Berkeley, Calif., the company is developing cell therapies for patients suffering from autoimmune and inflammatory diseases. Vida Ventures co-founder and senior managing director Fred Cohen will become the chairman of Kyverna's board.